Access to breast-conserving therapy still an issue for some patients
the ONA take:
According to a new study published in JAMA Surgery, researchers at The University of Texas MD Anderson Cancer Center in Houston, Texas, have found that the rates of breast-conserving therapy for early-stage breast cancer have increased, but access to this treatment modality still remains an issue for some patients.
For the study, researchers analyzed data from approximately 728,000 women with stage T1 or T2 breast cancer treated between 1998 and 2011 from the National Cancer Data Base. Researchers found that the proportion of patients undergoing breast-conserving therapy increased from 54.3% in 1998 to 59.7% in 2006, and leveled off at 60.1% in 2011.
Results showed that certain demographic factors, such as insurance, income, and travel distance to treatment facilities, impact which patients have access to breast-conserving therapy; however, declines in disparities related to age, geographic region, and treatment facility type were also observed.
The findings suggest that the majority of women are opting for breast-conserving therapy, but various disparities still exist that limit access to that treatment approach.
Rates of breast-conserving therapy for early-stage breast cancer have increased.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Open Hysterectomy Survival Rates Edge Minimally Invasive Procedures for Cervical Cancer
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|